Vitamin D Supplement Use Tied to Faster Cognitive Decline in a US Aging Cohort
In a nationally representative cohort of older US adults, vitamin D supplement use did not track with preserved cognition. It tracked with a faster fall in both global cognitive function and executive function over six years of follow-up.
The signal ran opposite to the long-held hope that vitamin D might help protect the aging brain. Among 5,065 participants in the Health and Retirement Study, 2,004 were taking vitamin D supplements at baseline. The cohort was older on average, with a mean age of 67.5 years, and most participants were White and female. Investigators then followed cognitive trajectories across HRS waves 12 through 15 using linear mixed models adjusted for multiple covariates.
The association was modest in absolute terms but consistent enough to merit attention. Compared with non-users, vitamin D users experienced an accelerated decline in global cognition at a rate difference of -0.052 points per year, with a 95% confidence interval from -0.092 to -0.013 and a p value of 0.010. Executive function showed a similar pattern, with a rate difference of -0.021 points per year, 95% confidence interval -0.037 to -0.005, also with p=0.010.
The Decline Appeared Most Clearly in Participants With Adequate Baseline Vitamin D
A single sensitivity result sharpened the interpretation. Accelerated cognitive decline showed up only among supplement users who already had normal baseline serum 25-hydroxyvitamin D levels, with p=0.004. It did not appear in participants with insufficient or deficient levels, where the association was null at p=0.826.
That pattern argues against a simple deficiency-replacement story. If vitamin D were acting mainly as a corrective therapy for low stores, the most vulnerable subgroup would be expected to benefit most. Instead, the association clustered in those who were already replete, which raises the possibility that supplementation without a clear indication may offer no cognitive advantage at all and could simply mark a different health profile, medication pattern, or underlying behavior that influences cognitive aging. The observational design cannot prove causation, but the direction of the signal is hard to ignore.
Cognition in later life is shaped by multiple intersecting processes, including vascular injury, neurodegeneration, inflammation, physical frailty, and educational or socioeconomic exposures across decades. Vitamin D has been linked biologically to neuroprotective hypotheses through immune modulation, neuronal signaling, and calcium homeostasis. Yet plausible mechanisms do not guarantee clinical benefit, especially when supplementation is layered onto a background of adequate nutritional status. In this cohort, the data did not support the idea that routine vitamin D use slows cognitive aging in older adults who are not deficient.
Cohort Design and Real-World Supplement Use Shape the Interpretation
The study’s strength lies in its real-world scale and longitudinal design. A prospective national cohort offers a more pragmatic view of vitamin D use than short-term trials limited by tightly controlled enrollment or narrow eligibility criteria. Here, the exposure was dietary supplement use in ordinary community-dwelling older adults, not a pharmacologic intervention under idealized conditions.
That same design also imposes a familiar caution. Supplement use in observational research can reflect health-seeking behavior, chronic disease burden, nutrition habits, physical activity, or pre-existing concerns about memory. Even with multivariable adjustment, residual confounding remains possible. People who choose supplements often differ from those who do not in ways that are difficult to measure precisely, and those differences can shape cognitive trajectories over time.
Still, the study’s longitudinal structure makes the finding clinically relevant. The analysis did not rely on a single cognitive snapshot. It examined change across six years, which is closer to the way clinicians encounter cognitive aging in practice: gradual, cumulative, and often subtle until function begins to slip.
What This Means at the Bedside
For older adults with documented vitamin D deficiency, supplementation remains appropriate for bone and mineral health, and it may still be indicated for other established reasons. This study does not challenge that standard practice. It does, however, argue against presenting vitamin D supplements as a cognitive safeguard for older adults who already have adequate levels.
The bedside consequence is straightforward. Routine vitamin D supplementation should not be recommended with the expectation that it will prevent cognitive decline in an older person who is already replete. Dietary intake and moderate sun exposure remain sensible ways to support adequate vitamin D status, but cognitive prevention should not be sold as a proven benefit of supplement use.
The findings also fit a broader pattern seen across many nutrition and cognition studies: biological plausibility can outpace clinical effectiveness. A nutrient can matter in deficiency without conferring extra neurologic protection once sufficiency is reached. In that setting, more is not necessarily better, and supplementation may become a habit sustained by public perception rather than measurable cognitive gain.
Why the Association May Look Harmful Rather Than Neutral
An observational association between supplement use and faster decline does not automatically mean vitamin D itself is harmful to the brain. The more likely explanation is that the exposure is functioning as a proxy for complex underlying factors that were not fully captured. Older adults taking supplements may differ in baseline health status, prior disease risk, or concerns about cognition that are already shaping their trajectory.
Even so, the lack of benefit in the sufficient subgroup weakens the argument for prophylactic supplementation as a cognitive strategy. If vitamin D were truly neuroprotective across the full range of baseline status, the effect would be expected to appear more broadly. Instead, the signal was confined to those with normal vitamin D levels, where any added supplement burden seems less likely to help and more likely to be clinically irrelevant for cognition.
For clinicians, the practical message is careful, not alarmist. Measure and correct deficiency when indicated. Avoid promising memory protection from vitamin D pills in older adults who are already sufficient. The cohort data do not support that claim, and the observed decline in function among users with normal baseline status makes routine supplementation for brain health a weak proposition.
The study leaves one central issue unresolved: whether the association reflects true biologic harm, unmeasured confounding, or both. What it does settle is narrower and more actionable — vitamin D supplementation should not be treated as a cognitive prevention strategy in older adults with adequate baseline vitamin D status.